Gender-specific effects of oral hypoglycaemic agents on cancer risk in type 2 diabetes mellitus

Diabetes, Obesity and Metabolism

Volumn 16, Issue 3, 2014, Pages 276-283

  Sun, G E C ^a   Wells, B J ^a   Yip, K ^b   Zimmerman, R ^a   Raghavan, D ^c   Kattan, M W ^a   Kashyap, S R ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b CLEVELAND CLINIC LERNER COLLEGE OF MEDICINE   (United States)

^c LEVINE CANCER INSTITUTE   (United States)

Author keywords

Biguanide; Cancer; Diabetes mellitus; Meglitinide; Sulphonylurea; Thiazolidinedione

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; BIGUANIDE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; MEGLITINIDE; SULFONYLUREA; TRIACYLGLYCEROL;

ADULT; AGE; ARTICLE; BODY MASS; BREAST CANCER; CANCER RISK; CEREBROVASCULAR ACCIDENT; CLEVELAND CLINIC DIABETES REGISTRY; DIASTOLIC BLOOD PRESSURE; DISEASE REGISTRY; FEMALE; FOLLOW UP; GENDER; GLOMERULUS FILTRATION RATE; HUMAN; INCOME; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; PROSTATE CANCER; RACE; RETROSPECTIVE STUDY; SYSTOLIC BLOOD PRESSURE; TOBACCO USE; TRANSIENT ISCHEMIC ATTACK;

BIGUANIDE; CANCER; DIABETES MELLITUS; MEGLITINIDE; SULPHONYLUREA; THIAZOLIDINEDIONE;

BENZAMIDES; BIGUANIDES; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INCIDENCE; MALE; MIDDLE AGED; NEOPLASMS; ODDS RATIO; OHIO; PROPORTIONAL HAZARDS MODELS; REGISTRIES; RETROSPECTIVE STUDIES; RISK; SEX FACTORS; SULFONYLUREA COMPOUNDS; THIAZOLIDINEDIONES;

EID: 84893767672     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12231     Document Type: Article

References (51)

1. Saydah SH, Loria CM, Eberhardt MS, Brancati FL. Abnormal glucose tolerance and the risk of cancer death in the United States. Am J Epidemiol 2003; 157: 1092-1100.
2. Bray GA, Bellanger T. Epidemiology, trends, and morbidities of obesity and the metabolic syndrome. Endocrine 2006; 29: 109-117.
3. Bowker SL, Majumdar SR, Veugelers P, Johnson JA. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care 2006; 29: 254-258.
4. Ramos-Nino ME, MacLean CD, Littenberg B. Association between cancer prevalence and use of thiazolidinediones: results from the Vermont diabetes information system. BMC Med 2007; 5: 17.
5. Bowker SL, Yasui Y, Veugelers P, Johnson JA. Glucose-lowering agents and cancer mortality rates in type 2 diabetes: Assessing effects of time-varying exposure. Diabetologia 2010; 53: 1631-1637.
6. Ish-Shalom D, Christoffersen CT, Vorwerk P et al. Mitogenic properties of insulin and insulin analogues mediated by the insulin receptor. Diabetologia 1997; 40(Suppl. 2): S25-S31.
7. Siddle K. Signalling by insulin and IGF receptors: supporting acts and new players. J Mol Endocrinol 2011; 47: R1-R10.
8. Lee MS, Hsu CC, Wahlqvist ML, Tsai HN, Chang YH, Huang YC. Type 2 diabetes increases and metformin reduces total, colorectal, liver and pancreatic cancer incidences in Taiwanese: a representative population prospective cohort study of 800, 000 individuals. BMC Cancer 2011; 11: 20.
9. Han S, Roman J. Rosiglitazone suppresses human lung carcinoma cell growth through PPARgamma-dependent and PPARgamma-independent signal pathways. Mol Cancer Thera 2006; 5: 430-437.
10. R Development Core Team (2011). R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. ISBN 3-900051-07-0. Available from URL: http://www.R-project.org/. Accessed 15 November 2012.
11. Harrell Jr FE (2011) rms: Regression Modeling Strategies. R package version 3.3-3. Available from URL: http://CRAN.R-project.org/package=rms. Accessed 5 January 2012.
12. van Buuren S, Groothuis-Oudshoorn K (2012) mice: Multivariate Imputation by Chained Equations. R package version 2.13. Available from URL: http://CRAN.R-project.org/package=mice. Accessed 8 September 2012.
13. van der Heijden GJ, Donders AR, Stijnen T, Moons KG. Imputation of missing values is superior to complete case analysis and the missing-indicator method in multivariable diagnostic research: A clinical example. J Clin Epidemiol 2006; 59: 1102-1109.
14. Currie CJ, Poole CD, Gale EAM. The influence of glucose lowering therapies on cancer risk in type 2 diabetes. Diabetologia 2009; 52: 1766-1777.
15. Li D, Yeung SC, Hassan MM, Konopleva M, Abbruzzese JL. Antidiabetic therapies affect risk of pancreatic cancer. Gastroenterology 2009; 137: 482-488.
16. Rubin DB. Multiple imputation for nonresponse in surveys. multiple imputation for nonresponse in surveys. New York: Wiley, 1987.
17. Howlader N, Noone AM, Krapcho M et al. SEER Cancer Statistics Review, 1975-2008, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2008/, based on November 2010 SEER data submission, posted to the SEER web site 2011. Accessed 11 September 2012.
18. Michels KB, Solomon CG, Hu FB et al. Type 2 diabetes and subsequent incidence of breast cancer in the Nurses' Health Study. Diabetes Care 2003; 26: 1752-1758.
19. Xue F, Michels KB. Diabetes, metabolic syndrome, and breast cancer: a review of the current evidence. Am J Clin Nutr 2007; 86: 823S-835S.
20. Peairs KS, Barone BB, Snyder CF et al. Diabetes mellitus and breast cancer outcomes: a systematic review and meta-analysis. J Clin Oncol 2011; 29: 40-46.
21. Schrauder MG, Fasching PA, Haberle L et al. Diabetes and prognosis in a breast cancer cohort. J Cancer Res Clin Oncol 2011; 137: 975-983.
22. Pasanisi P, Berrino F, De Petris M, Venturelli E, Mastroianni A, Panico S. Metabolic syndrome as a prognostic factor for breast cancer recurrences. Int J Cancer 2006; 119: 236-238.
23. Chodick G, Heymann AD, Rosenmann L et al. Diabetes and risk of incident cancer: a large population-based cohort study in Israel. Cancer Causes Control 2010; 21: 879-887.
24. Larsson SC, Orsini N, Brismar K, Wolk A. Diabetes mellitus and risk of bladder cancer: a meta-analysis. Diabetologia 2006; 49: 2819-2823.
25. Calton BA, Change SC, Wright ME et al. History of diabetes mellitus and subsequent prostate cancer risk in the NIH-AARP Diet and Health Study. Cancer Causes Control 2007; 18: 493-503.
26. Gong Z, Neuhouser ML, Goodman PJ et al. Obesity, diabetes and risk of prostate cancer: results from the prostate cancer prevention trial. Cancer Epidemiol Biomarkers Prev 2006; 15: 1977-1983.
27. Rodriguez C, Patel AV, Mondul AM, Jacobs EJ, Thun MJ, Calle EE. Diabetes and risk of prostate cancer in a prospective cohort of US men. Am J Epidemiol 2005; 161: 147-152.
28. Will JC, Vinicor F, Calle EE. Is diabetes mellitus associated with prostate cancer incidence and survival. Epidemiology 1999; 10: 313-318.
29. Papa V, Pezzino V, Costantino A et al. Elevated insulin receptor content in human breast cancer. J Clin Invest 1990; 86: 1503-1510.
30. Novosyadlyy R, Lann DE, Vijayakumar A et al. Insulin-mediated acceleration of breast cancer development and progression in a nonobese model of type 2 diabetes. Cancer Res 2010; 70: 741-751.
31. Beauchamp MC, Yasmeen A, Knafo A, Gotlieb WH. Targeting insulin and insulin-like growth factor pathways in epithelial ovarian cancer. J Oncol 2010; 2010: 257058.
32. Masur K, Vetter C, Hinz A et al. Diabetogenic glucose and insulin concentrations modulate transcriptome and protein levels involved in tumour cell migration, adhesion, and proliferation. Br J Cancer 2011; 104: 345-352.
33. Leung KC, Doyle N, Ballesteros M, Waters MJ, Ho KK. Insulin regulation of human hepatic growth hormone receptors: divergent effects on biosynthesis and surface translocation. J Clin Endocrinol Metab 2000; 85: 4712-4720.
34. Frystyk J, Vestbo E, Skjaerbaek C, Mogensen CE, Orskov H. Free insulin-like growth factors in human obesity. Metabolism 1995; 44(Suppl. 4): 35-44.
35. Wolf I, Sadetzki S, Catane R, Karasik A, Kaufman B. Diabetes mellitus and breast cancer. Lancet Oncol 2005; 6: 103-111.
36. Soranna D, Scotti L, Zambon A et al. Cancer risk associated with use of metformin and sulfonylurea in type 2 diabetes: a meta-analysis. Oncologist 2012; 17: 813-822.
37. Storozhuk Y, Hopmans SN, Sanli T et al. Metformin inhibits growth and enhances radiation response of non-small cell lung cancer (NSCLC) through ATM and AMPK. Br J Cancer 2013; 108: 2021-2032.
38. Mazzone PJ, Rai H, Beukemann M, Xu M, Jain A, Sasidhar M. The effect of metformin and thiazolidinedione use on lung cancer in diabetics. BMC Cancer 2012; 12: 410.
39. Lai SW, Liao KF, Chen PC, Tsai PY, Hsieh DP, Chen CC. Antidiabetes drugs correlate with decreased risk of lung cancer: a population-based observation in Taiwan. Clin Lung Cancer 2012; 13: 143-148.
40. Govindarajan R, Ratnasinghe L, Simmons DL et al. Thiazolidinediones and the risk of lung, prostate, and colon cancer in patients with diabetes. J Clin Oncol 2007; 25: 1476-1481.
41. He X, Esteva FJ, Ensor J, Hortobagy GN, Lee MH, Yeung SCJ. Metformin and thiazolidinediones are associated with improved breast cancer-specific survival of diabetic women with HER2+ breast cancer. Ann Oncol 2011; 23: 1771-1780.
42. Colmers IN, Bowker SL, Majumdar SR, Johnson JA. Use of thiazolidinediones and the risk of bladder cancer among people with type 2 diabetes: a meta-analysis. CMAJ 2012; 184: E675-E683.
43. Wudy SA, Hogel J, Dollinger B, Mullis P, Heinze E. Glimepiride treatment and IGF-I in adolescents with type 1 diabetes: a prospective, randomized, double-blind, placebo-controlled study. Diabetes Care 2003; 26: 1312-1313.
44. Gullo L, Pezzilli R, Morselli-Labate AM, Italian Pancreatic Cancer Study Group. Diabetes and the risk of pancreatic cancer. N Engl J Med 1994; 331: 81-84.
45. Giouleme O, Diamantidis MD, Katsaros MG. Is diabetes a causal agent for colorectal cancer? Pathophysiological and molecular mechanisms. World J Gastroenterol 2011; 17: 444-448.
46. Nilsen TI, Vatten LJ. Prospective study of colorectal cancer risk and physical activity, diabetes, blood glucose and BMI: exploring the hyperinsulinaemia hypothesis. Br J Cancer 2001; 84: 417-422.
47. Alsheikh-Ali AA, Trikalinos TA, Kent DM, Karas RH. Statins, low-density lipoprotein cholesterol, and risk of cancer. J Am Coll Cardiol 2008; 52: 1141-1147.
48. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation 2002; 105: 1135-1143.
49. Giovannucci E, Harlan DM, Archer MC et al. Diabetes and cancer: a consensus report. CA Cancer J Clin 2010; 60: 207-221.
50. Centers for Disease Control and Prevention, FastStats (2009). Available from URL: http://www.cdc.gov/features/cancerstatistics/. Accessed 10 September 2012.
51. Davila JA, Morgan RO, Shaib Y, McGlynn KA, El-Serag HB. Diabetes increases the risk of hepatocellular carcinoma in the United States: a population based case control study. Gut 2005; 54: 533-539.